# Lite Strategy, Inc.: financial statements, quarterly

LITS · Nasdaq · CIK 1262104 · [Financials](/sectors/financials.md) · fiscal year ends Jun 30

Pages: [Overview](/companies/lits.md) · [Financials](/companies/lits/financials.md) · [Filings](/companies/lits/filings.md) · [Insiders](/companies/lits/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lits/financials.md?period=annual).

## Income statement

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [65.3](/filings/0000950170-24-125328.md) | [0.0](/filings/0000950170-25-018809.md) | [0.0](/filings/0000950170-25-070276.md) | [0.0 d](/filings/0001193125-25-220421.md) | [0.0](/filings/0000950170-24-125328.md) | [0.0](/filings/0000950170-25-018809.md) | [0.0](/filings/0000950170-25-070276.md) | [0.0 d](/filings/0001193125-25-220421.md) | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | [3.5](/filings/0000950170-24-125328.md) | [3.9](/filings/0000950170-25-018809.md) | [5.2](/filings/0000950170-25-070276.md) | [3.9 d](/filings/0001193125-25-220421.md) | [3.2](/filings/0001193125-25-283111.md) | [0.3](/filings/0001193125-26-053215.md) | [0.4](/filings/0001193125-26-220687.md) | [0.1 d](/filings/0001193125-26-405328.md) | [0.0](/filings/0001193125-25-283111.md) | [0.0](/filings/0001193125-26-053215.md) | [0.0](/filings/0001193125-26-220687.md) | [0.0 d](/filings/0001193125-26-405328.md) |
| Operating income | $m | [55.3](/filings/0000950170-24-125328.md) | [(11.9)](/filings/0000950170-25-018809.md) | [(9.8)](/filings/0000950170-25-070276.md) | [(19.0) d](/filings/0001193125-25-220421.md) | [(8.4)](/filings/0001193125-25-283111.md) | [(3.5)](/filings/0001193125-26-053215.md) | [(2.8)](/filings/0001193125-26-220687.md) | [(2.9) d](/filings/0001193125-26-405328.md) | [(3.7)](/filings/0001193125-25-283111.md) | [(29.9)](/filings/0001193125-26-053215.md) | [(21.6)](/filings/0001193125-26-220687.md) | [(11.4) d](/filings/0001193125-26-405328.md) |
| Income tax | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Net income | $m | [56.4](/filings/0000950170-25-070276.md) | [(11.1)](/filings/0000950170-25-070276.md) | [(9.1)](/filings/0000950170-25-070276.md) | [(18.2) d](/filings/0001193125-26-405328.md) | [(8.0)](/filings/0001193125-26-220687.md) | [(2.7)](/filings/0001193125-26-220687.md) | [(2.6)](/filings/0001193125-26-220687.md) | [(2.7) d](/filings/0001193125-26-405328.md) | [(3.6)](/filings/0001193125-26-220687.md) | [(30.8)](/filings/0001193125-26-220687.md) | [(23.7)](/filings/0001193125-26-220687.md) | [(13.0) d](/filings/0001193125-26-405328.md) |
| Diluted EPS | $ per share | [8.46](/filings/0000950170-24-125328.md) | [(1.66)](/filings/0000950170-25-018809.md) | [(1.37)](/filings/0000950170-25-070276.md) | not reported | [(1.20)](/filings/0001193125-25-283111.md) | [(0.40)](/filings/0001193125-26-053215.md) | [(0.39)](/filings/0001193125-26-220687.md) | not reported | [(0.12)](/filings/0001193125-25-283111.md) | [(0.82)](/filings/0001193125-26-053215.md) | [(0.66)](/filings/0001193125-26-220687.md) | not reported |
| Basic EPS | $ per share | [8.46](/filings/0000950170-24-125328.md) | [(1.66)](/filings/0000950170-25-018809.md) | [(1.37)](/filings/0000950170-25-070276.md) | not reported | [(1.20)](/filings/0001193125-25-283111.md) | [(0.40)](/filings/0001193125-26-053215.md) | [(0.39)](/filings/0001193125-26-220687.md) | not reported | [(0.12)](/filings/0001193125-25-283111.md) | [(0.82)](/filings/0001193125-26-053215.md) | [(0.66)](/filings/0001193125-26-220687.md) | not reported |

- Revenue: us-gaap:Revenues
- Cost of revenue: not reported
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: not reported
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [3.4](/filings/0000950170-23-061976.md) | [5.2](/filings/0000950170-24-014640.md) | [2.4](/filings/0000950170-24-056834.md) | [3.7](/filings/0001193125-25-220421.md) | [7.0](/filings/0000950170-24-125328.md) | [23.7](/filings/0000950170-25-018809.md) | [20.5](/filings/0000950170-25-070276.md) | [18.0](/filings/0001193125-26-405328.md) | [10.1](/filings/0001193125-25-283111.md) | [8.8](/filings/0001193125-26-053215.md) | [7.5](/filings/0001193125-26-220687.md) | [5.7](/filings/0001193125-26-405328.md) |
| Current assets | $m | [88.4](/filings/0000950170-23-061976.md) | [66.2](/filings/0000950170-24-014640.md) | [59.4](/filings/0000950170-24-056834.md) | [40.8](/filings/0001193125-25-220421.md) | [27.7](/filings/0000950170-24-125328.md) | [24.4](/filings/0000950170-25-018809.md) | [20.8](/filings/0000950170-25-070276.md) | [18.3](/filings/0001193125-26-405328.md) | [13.2](/filings/0001193125-25-283111.md) | [10.9](/filings/0001193125-26-053215.md) | [11.0](/filings/0001193125-26-220687.md) | [6.1](/filings/0001193125-26-405328.md) |
| Total assets | $m | [101](/filings/0000950170-23-061976.md) | [78.5](/filings/0000950170-24-014640.md) | [71.3](/filings/0000950170-24-056834.md) | [41.4](/filings/0001193125-25-220421.md) | [27.8](/filings/0000950170-24-125328.md) | [24.4](/filings/0000950170-25-018809.md) | [20.8](/filings/0000950170-25-070276.md) | [18.3](/filings/0001193125-26-405328.md) | [113](/filings/0001193125-25-283111.md) | [82.9](/filings/0001193125-26-053215.md) | [57.8](/filings/0001193125-26-220687.md) | [42.7](/filings/0001193125-26-405328.md) |
| Current liabilities | $m | [8.6](/filings/0000950170-23-061976.md) | [8.0](/filings/0000950170-24-014640.md) | [9.6](/filings/0000950170-24-056834.md) | [8.4](/filings/0001193125-25-220421.md) | [2.9](/filings/0000950170-24-125328.md) | [2.3](/filings/0000950170-25-018809.md) | [1.2](/filings/0000950170-25-070276.md) | [1.4](/filings/0001193125-26-405328.md) | [1.1](/filings/0001193125-25-283111.md) | [1.1](/filings/0001193125-26-053215.md) | [1.0](/filings/0001193125-26-220687.md) | [1.1](/filings/0001193125-26-405328.md) |
| Total liabilities | $m | [19.9](/filings/0000950170-23-061976.md) | [19.1](/filings/0000950170-24-014640.md) | [20.2](/filings/0000950170-24-056834.md) | [8.4](/filings/0001193125-25-220421.md) | [2.9](/filings/0000950170-24-125328.md) | [2.3](/filings/0000950170-25-018809.md) | [1.2](/filings/0000950170-25-070276.md) | [1.4](/filings/0001193125-26-405328.md) | [1.1](/filings/0001193125-25-283111.md) | [1.1](/filings/0001193125-26-053215.md) | [1.0](/filings/0001193125-26-220687.md) | [1.1](/filings/0001193125-26-405328.md) |
| Shareholders' equity | $m | [81.4](/filings/0000950170-25-070276.md) | [59.5](/filings/0000950170-25-070276.md) | [51.0](/filings/0000950170-25-070276.md) | [33.0](/filings/0001193125-26-405328.md) | [24.9](/filings/0001193125-26-220687.md) | [22.1](/filings/0001193125-26-220687.md) | [19.5](/filings/0001193125-26-220687.md) | [16.9](/filings/0001193125-26-405328.md) | [112](/filings/0001193125-26-220687.md) | [81.9](/filings/0001193125-26-220687.md) | [56.8](/filings/0001193125-26-220687.md) | [41.6](/filings/0001193125-26-405328.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q4 FY2024 (2024-06-30) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q4 FY2025 (2025-06-30) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) | Q4 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(18.5)](/filings/0000950170-24-125328.md) | [(11.1) d](/filings/0000950170-25-018809.md) | [(2.9) d](/filings/0000950170-25-070276.md) | [(18.0) d](/filings/0001193125-25-220421.md) | [(11.5)](/filings/0001193125-25-283111.md) | [(3.7) d](/filings/0001193125-26-053215.md) | [(3.3) d](/filings/0001193125-26-220687.md) | [(2.5) d](/filings/0001193125-26-405328.md) | [(4.5)](/filings/0001193125-25-283111.md) | [(1.9) d](/filings/0001193125-26-053215.md) | [(1.5) d](/filings/0001193125-26-220687.md) | [(1.2) d](/filings/0001193125-26-405328.md) |
| Capital expenditure | $m | [0.0](/filings/0000950170-23-061976.md) | [0.0 d](/filings/0000950170-25-018809.md) | [0.0 d](/filings/0000950170-25-070276.md) | [0.0 d](/filings/0001193125-25-220421.md) | not reported | not reported | [0.0 d](/filings/0000950170-25-070276.md) | [0.0 d](/filings/0001193125-25-220421.md) | not reported | not reported | not reported | not reported |
| Dividends paid | $m | not reported | not reported | [0.0 d](/filings/0000950170-25-070276.md) | [0.0 d](/filings/0001193125-25-220421.md) | not reported | not reported | [0.0 d](/filings/0000950170-25-070276.md) | [0.0 d](/filings/0001193125-25-220421.md) | not reported | not reported | not reported | not reported |
| Share repurchases | $m | not reported | not reported | not reported | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-220687.md) | [0.0 d](/filings/0001193125-26-405328.md) | not reported | not reported | [1.8 d](/filings/0001193125-26-220687.md) | [2.9 d](/filings/0001193125-26-405328.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: us-gaap:PaymentsOfDividends
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2022-09-30) | Q2 FY2023 (2022-12-31) | Q3 FY2023 (2023-03-31) | Q1 FY2024 (2023-09-30) | Q2 FY2024 (2023-12-31) | Q3 FY2024 (2024-03-31) | Q1 FY2025 (2024-09-30) | Q2 FY2025 (2024-12-31) | Q3 FY2025 (2025-03-31) | Q1 FY2026 (2025-09-30) | Q2 FY2026 (2025-12-31) | Q3 FY2026 (2026-03-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [6.7](/filings/0000950170-23-061976.md) | [6.7](/filings/0000950170-24-014640.md) | [6.7](/filings/0000950170-24-056834.md) | [6.7](/filings/0000950170-24-125328.md) | [6.7](/filings/0000950170-25-018809.md) | [6.7](/filings/0000950170-25-070276.md) | [6.7](/filings/0001193125-25-283111.md) | [6.7](/filings/0001193125-26-053215.md) | [6.7](/filings/0001193125-26-220687.md) | [29.5](/filings/0001193125-25-283111.md) | [37.4](/filings/0001193125-26-053215.md) | [35.7](/filings/0001193125-26-220687.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 30,407,268 at 2026-09-22, from the cover of the [10-K filed 2026-09-28](/filings/0001193125-26-405328.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:35 ET. No prices; not investment advice.